Vascular-targeting agent

A vascular-targeting agent (VTA) or vascular disrupting agent (VDA) is a drug designed to damage the vasculature (blood vessels) of cancer tumors causing central necrosis.^[1]

VTAs can be small-molecule or ligand-based.

Small-molecule VTAs include:

• microtubule destabilizing drugs such as combretastatin A-4 disodium phosphate (CA4P), ZD6126, AVE8062, Oxi 4503
• vadimezan (ASA404)

Clinical trials

Phase II : ZD6126, CA4P, NPI-2358^[2]

Phase III : DMXAA (ASA404).

References